Hancock Jaffe Laboratories Inc (HJLI) Stock Price & Overview
NASDAQ:HJLI
Current stock price
The current stock price of HJLI is 10.38 null. Today HJLI is down by -1.98%. In the past month the price increased by 33.76%. In the past year, price decreased by -3.67%.
HJLI Key Statistics
- Market Cap
- 90.15M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.47
- Dividend Yield
- N/A
HJLI Stock Performance
HJLI Stock Chart
HJLI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to HJLI. When comparing the yearly performance of all stocks, HJLI is one of the better performing stocks in the market, outperforming 77.04% of all stocks.
HJLI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HJLI. HJLI has a great financial health rating, but its profitability evaluates not so good.
HJLI Earnings
HJLI Forecast & Estimates
1 analysts have analysed HJLI and the average price target is 26.52 null. This implies a price increase of 155.49% is expected in the next year compared to the current price of 10.38.
HJLI Financial Highlights
Over the last trailing twelve months HJLI reported a non-GAAP Earnings per Share(EPS) of -4.47. The EPS increased by 48.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.15% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
HJLI Ownership
HJLI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 39.25 | 162.529B | ||
| ABT | ABBOTT LABORATORIES | 14.24 | 157.763B | ||
| SYK | STRYKER CORP | 17.41 | 120.688B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.31 | 85.619B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.9 | 48.141B | ||
| IDXX | IDEXX LABORATORIES INC | 38.32 | 44.539B | ||
| BDX | BECTON DICKINSON AND CO | 10.94 | 42.438B | ||
| RMD | RESMED INC | 16.7 | 31.148B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 10.74 | 27.761B | ||
| DXCM | DEXCOM INC | 20.18 | 22.918B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.11 | 15.956B | ||
| PEN | PENUMBRA INC | 63.83 | 12.837B | ||
| GMED | GLOBUS MEDICAL INC - A | 20.03 | 12.197B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HJLI
Company Profile
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 19 full-time employees. The company went IPO on 2018-05-31. The firm is engaged in developing tissue based devices that are designed for patients with cardiovascular disease, and peripheral arterial and venous disease. The firm's product includes VenoValve and CoreoGraft. VenoValve is a device surgically implanted in the deep venous system of the leg to treat a debilitating condition called chronic venous insufficiency (CVI). CoreoGraft is a bovine based conduit to be used to revascularize the heart during coronary artery bypass graft (CABG) surgeries.
Company Info
IPO: 2018-05-31
Hancock Jaffe Laboratories Inc
70 Doppler
Irvine CALIFORNIA 92618 US
CEO: Robert Berman
Employees: 19
Phone: 19492612900.0
Hancock Jaffe Laboratories Inc / HJLI FAQ
What does Hancock Jaffe Laboratories Inc do?
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 19 full-time employees. The company went IPO on 2018-05-31. The firm is engaged in developing tissue based devices that are designed for patients with cardiovascular disease, and peripheral arterial and venous disease. The firm's product includes VenoValve and CoreoGraft. VenoValve is a device surgically implanted in the deep venous system of the leg to treat a debilitating condition called chronic venous insufficiency (CVI). CoreoGraft is a bovine based conduit to be used to revascularize the heart during coronary artery bypass graft (CABG) surgeries.
What is the current price of HJLI stock?
The current stock price of HJLI is 10.38 null. The price decreased by -1.98% in the last trading session.
Does HJLI stock pay dividends?
HJLI does not pay a dividend.
What is the ChartMill rating of Hancock Jaffe Laboratories Inc stock?
HJLI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for HJLI stock?
1 analysts have analysed HJLI and the average price target is 26.52 null. This implies a price increase of 155.49% is expected in the next year compared to the current price of 10.38.
Can you provide the market cap for Hancock Jaffe Laboratories Inc?
Hancock Jaffe Laboratories Inc (HJLI) has a market capitalization of 90.15M null. This makes HJLI a Micro Cap stock.
Can you provide the ownership details for HJLI stock?
You can find the ownership structure of Hancock Jaffe Laboratories Inc (HJLI) on the Ownership tab.